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Translational medicine is a new emerging medical practice 
comprising multidisciplinary research from basic sciences 
to clinical medicine. It is regarded as a two-way road: bench 
to bedside and bedside to bench, playing important roles in 
communications between basic and clinical scientists [1]. 
As a developing country with more than 1.3 billion people, 
China bears a complex disease spectrum. It is thus urgent 
for China to develop translational medicine to facilitate pre-
diction, prevention, diagnosis, and treatment of diseases. 
With the energetic supports of governments and scientists, 
translational medicine in China has developed rapidly in 
recent years. The 12th issue of Science China Life Sciences 
in 2011 organizes a special issue––Translational medicine 
in China I: Perspectives from Chinese physicians and scien-
tists [2], focusing on translational medicine in China with 
five reviews, making a comprehensive introduction to the 
current circumstance of translational medicine in China. 
With increasing attention and rapid development of bio-
logical research, many remarkable basic science discoveries 
about life have been achieved. Unfortunately, due to the 
limited communications between basic and clinical scien-
tists, these valuable laboratory discoveries are difficult to be 
translated into clinical applications. This has opened up the 
demand for bridging between basic science and clinical use. 
The concept of translational medicine has emerged in recent 
years under this circumstance, aiming to facilitate the con-
version of laboratory discoveries into clinical applications. 
The first issue of the Journal of Translational Medicine in 
2003 formally declared translational medicine as a new dis-
cipline. Since then, translational medicine has developed 
rapidly and widely. Scientists all around the world have 
made many successful studies in translational medicine 
[36], greatly enhancing our understanding of translational 
medicine, and paving the way to more fruitful translational 
results. Actually, even before the appearance of the concept 
of translational medicine, there have already been many 
successful translational studies based on the bedside- 
to-bench-to-bedside translational strategy. The review enti-
tled “Translational research: Lessons from past research, 
growing up nowadays, and development goal in future” by 
Zhang et al. [7] provides many successful examples of these 
classical translational studies, including the Framingham 
Heart Study and the development of statins to percutaneous 
coronary intervention treatment. Another review entitled 
“Liu Shih-Hao: Pioneer of translational medicine in China” 
by Li [8] reviews the research, teaching and clinical work of 
Liu Shih-Hao, who is regarded as the pioneer of translation-
al medicine in China. Dr. Liu’s early work in calcium and 
phosphorus metabolism is a well-known success story of 
translational medicine, which is still important and revela-
tory until now.  
As a country with the largest population in the world, 
China bears a complex disease spectrum, from communica-
ble diseases such as hepatitis B virus, tuberculosis and ac-
quired immunodeficiency syndrome (AIDS) to chronic dis-
eases including cancer, heart disease and hypertension. 
With the ultimate goal to develop more effective preven-
tive/therapeutic approaches and improve clinical outcomes 
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and health levels, translational medicine is therefore essen-
tial for China’s health system. The first review entitled 
“Translational medicine should translate medical science 
and technology into health care for everyone in China” by 
Chen and Zhou [9] indicates that translational medicine 
should focus on patients and the general population, points 
out the importance of translational research for China’s 
health industry, and also discusses proper principles for 
development of translational medicine in China. With sup-
port of the governments and scientists, especially financial 
supports, translational medicine in China has developed 
rapidly in recent years. The first Symposium on Transla-
tional Medicine in 2007 and the Sino-America Symposium 
on Clinical and Translational Research in June 2010 em-
phasize the commitment of China to the rapid development 
of translational medicine [10]. As the wave of translational 
medicine sweeping across the world, increasingly more ex-
cellent Chinese physicians and scientists have emerged, 
who have conducted remarkable work, enhancing the de-
velopment of translational medicine. To take one example, 
the review entitled “Overview the theory on molecular tar-
geted therapy, its features and future direction, and contri-
butions in the field from Chinese scientists” by Liu et al. 
[11] displays the contributions of Chinese scientists to mo-
lecular targeted therapy (MTT), which has promising poten-
tial to kill tumors and induce tumor cells to differentiate into 
normal cells, leading to cure of the patients.  
It is noteworthy that translational medicine in China has 
its own characteristics: moving traditional Chinese medicine 
(TCM) from empirical to evidence-based practicing. As 
widely practiced healing theories and practices for almost 
2000 years, TCM is still popular in China now. There are 
many successful cases of translation from traditional Chi-
nese medicine, providing Chinese clinicians with an im-
portant interpretation of translational medicine. The review 
entitled “Translational medicine: What is in a name from 
the perspective of Chinese clinicians?” by Zeng and Zhong 
[12] describes these successful examples of translation from 
traditional Chinese medicine, including the use of artemis-
inin in the management of malaria, the use of arsenic in the 
management of leukemia, and artificial infection with ma-
laria parasites for lung cancer therapy [13–15]. 
Although translational medicine has developed rapidly in 
recent years, there remain several obstacles, including lack 
of sufficient funding, high cost and slow results, shortage of 
researchers, inadequate samples, and incompatible data- 
bases [16,17]. Further development of translational medi-
cine requires more sources of funding and education, and 
the most important strategy to promote translational re-
search is to decrease the cost by increasing its efficiency. 
For China, development of translational medicine will 
largely depend on collaboration between China and other 
countries, sharing the understanding, methodologies, re-
search protocols and resources, and development. It is be-
lieved that translational medicine in China will realize a 
leapfrog development in the near future.  
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